Article

Targeting KRAS G12C and G12S mutations in lung cancer: In silico drug repurposing and antiproliferative assessment on A549 cells

2025-01-01

Abstract excerpt

The RAS protein is a notable target in cancer research, being the most often mutated oncogene in human malignancies. The RAS G12X mutation is predominantly found in non-small cell lung cancer, including G12C and G12S variants, which are associated with a poor prognosis. Despite the approval of two inhibitors for the KRAS G12C mutation (sotorasib and adagrasib), the necessity persists due to the emergence of resist...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d19e00d9-7bd0-581e-93f7-7b26f574e195
DOI: 10.1016/j.imu.2024.101612

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting KRAS G12C and G12S mutations in lung cancer: In silico drug repurposing and antiproliferative assessment on A549 cellsDOI 10.1016/j.imu.2024.101612Read

Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study.Semantic proximity Read

KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.Semantic proximity Read

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.Semantic proximity Read

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways.Semantic proximity Read

Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer.Semantic proximity Read

Identification of Noncovalent Small-Molecules from Virtual Screening Toward the Development of Potential KRAS Inhibitors.Semantic proximity Read

Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRASG12C.Semantic proximity Read

An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer.Semantic proximity Read

Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.Semantic proximity Read

Computational study of novel natural inhibitors targeting Kirsten rat sarcoma viral oncogene homolog G12C.Semantic proximity Read

In silico comparative analysis of KRAS mutations at codons 12 and 13: Structural modifications of P-Loop, switch I&II regions preventing GTP hydrolysis.Semantic proximity Read

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.Semantic proximity Read